Fenwal Inc. and Golden Meditech Co. Ltd. have agreed to form a joint venture in China to focus on blood collection and transfusion products for the Chinese medical market. The joint venture will operate from Beijing and serve customers throughout China. Initially, the joint venture will focus on sales and distribution of a range of Fenwal and Golden Meditech products, including Fenwal's Amicus system, a cell-separation system used to collect platelets; Golden Meditech's 3000H Plasma Exchange system, which is designed to remove toxins from patients' blood; and related supplies used to collect, process, preserve and transfuse blood and blood components. Medical professionals in China are expected to benefit from the combination of Fenwal's technological leadership in blood collection, separation, preservation and transfusion, and Golden Meditech's expertise in China's blood-related medical device and blood-banking fields. Fenwal will own 51% of the joint venture and Golden Meditech will own 49%. The transaction is expected to be completed in early 2010, subject to the signing of a definitive agreement and other customary company and regulatory conditions.

Golden Meditech Co. Ltd. reported earnings results for the year ended March 31, 2009. For the period, the company profit from operations of HKD 220,043,000 compared to HKD 535,311,000 for the same period a year ago. Profit before taxation was HKD 122,331,000 compared to HKD 638,756,000 for the same period a year ago. Profit for the year from continuing operations was HKD 80,336,000 or 3.6 cents diluted per share compared to HKD 614,512,000 or 36.3 cents diluted per share for the same period a year ago. Net cash generated from operating activities was HKD 53,330,000 compared to HKD 212,136,000 for the same period a year ago. Payment for acquisition of property, plant and equipment was HKD 40,812,000 compared to HKD 19,475,000 for the same period a year ago.

Golden Meditech Co. Ltd., Annual General Meeting, Aug 28, 2009, at 10:00 CCT-China Coast, USSR Zone 7. Location: Everest Room, Swire Properties Conference Centre, Level 5, One Pacific Place, 88 Queensway, Hong Kong. Agenda: To consider the audited consolidated financial statements of the company and its subsidiaries and the reports of the directors of the company and of the auditors for the year ended 31 March 2009; to re-elect retiring directors; to approve the directors to fix the directors' remuneration; to re-appoint the retiring auditors, KPMG, and to authorise the directors to fix their remuneration; to consider and, if thought fit, pass with or without amendments, the authorised share capital of the company be and is hereby increased from HKD 200,000,000.00 divided into 2,000,000,000 shares of HKD 0.10 each (the 'shares') to HKD 400,000,000.00 by the creation of 2,000,000,000 new shares.